190 related articles for article (PubMed ID: 10617686)
1. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme AM
Mol Pharmacol; 2000 Jan; 57(1):116-24. PubMed ID: 10617686
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication.
Hamy F; Felder ER; Heizmann G; Lazdins J; Aboul-ela F; Varani G; Karn J; Klimkait T
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3548-53. PubMed ID: 9108013
[TBL] [Abstract][Full Text] [Related]
3. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.
Litovchick A; Lapidot A; Eisenstein M; Kalinkovich A; Borkow G
Biochemistry; 2001 Dec; 40(51):15612-23. PubMed ID: 11747436
[TBL] [Abstract][Full Text] [Related]
4. Blocking HIV replication by targeting Tat protein.
Hamy F; Gelus N; Zeller M; Lazdins JL; Bailly C; Klimkait T
Chem Biol; 2000 Sep; 7(9):669-76. PubMed ID: 10980447
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication.
Maréchal V; Arenzana-Seisdedos F; Heard JM; Schwartz O
J Virol; 1999 May; 73(5):3608-15. PubMed ID: 10196252
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
7. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions.
O'Brien WA; Sumner-Smith M; Mao SH; Sadeghi S; Zhao JQ; Chen IS
J Virol; 1996 May; 70(5):2825-31. PubMed ID: 8627756
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.
Lalonde MS; Lobritz MA; Ratcliff A; Chamanian M; Athanassiou Z; Tyagi M; Wong J; Robinson JA; Karn J; Varani G; Arts EJ
PLoS Pathog; 2011 May; 7(5):e1002038. PubMed ID: 21625572
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.
Mhashilkar AM; Biswas DK; LaVecchio J; Pardee AB; Marasco WA
J Virol; 1997 Sep; 71(9):6486-94. PubMed ID: 9261367
[TBL] [Abstract][Full Text] [Related]
10. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of an HIV-1 Tat antagonist.
Hsu MC; Schutt AD; Holly M; Slice LW; Sherman MI; Richman DD; Potash MJ; Volsky DJ
Biochem Soc Trans; 1992 May; 20(2):525-31. PubMed ID: 1397654
[TBL] [Abstract][Full Text] [Related]
12. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.
Daelemans D; Esté JA; Witvrouw M; Pannecouque C; Jonckheere H; Aquaro S; Perno CF; De Clercq E; Vandamme AM
Mol Pharmacol; 1997 Dec; 52(6):1157-63. PubMed ID: 9396786
[TBL] [Abstract][Full Text] [Related]
13. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat.
Ghezzi S; Noonan DM; Aluigi MG; Vallanti G; Cota M; Benelli R; Morini M; Reeves JD; Vicenzi E; Poli G; Albini A
Biochem Biophys Res Commun; 2000 Apr; 270(3):992-6. PubMed ID: 10772939
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction.
Hamasaki T; Okamoto M; Baba M
Antimicrob Agents Chemother; 2013 Mar; 57(3):1323-31. PubMed ID: 23274668
[TBL] [Abstract][Full Text] [Related]
19. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
20. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
